clinical trial · NCT04980482
Open-Label Study of AB-729, Nucleos(t)Ide Analogue and Pegylated Interferon Alfa-2a in Subjects With Chronic Hepatitis B Infection
Chronic Hepatitis bAB-729Peg-IFNα-2a
brief summary
This is a randomized, open label, multicenter Phase 2 study investigating the safety and antiviral activity of AB-729 in combination with ongoing NA therapy and short courses of Peg-IFNα-2a in subjects with CHB.
started
Oct 29, 2021
primary completion
Mar 13, 2025
completion
May 21, 2025
last updated
Oct 22, 2025
official title
A Randomized, Open-Label, Multicenter Study Investigating AB-729, Nucleos(t)Ide Analogue and Pegylated Interferon Alfa-2a Treatment in Subjects With Chronic Hepatitis B Infection
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol